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ABSTRACT 
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that may result 
from defective functions of the immunoregulatory T cell circuits. Cytokines play an 
essential role in molding the quality of an immune response to foreign or self-antigens. 
With the growing literature regarding cytokine production in autoimmune diseases, an 
important role for an active Th 1 response, characterized by production of IFN-y, IL-2, fL-
12 and TNF-a has become evident. On the contrary, there have also been repeated 
observations of high levels of type 2 cytokines (IL-4, IL-5, IL-l 0, IL-6 and IL-13) 
particularly in the systemic autoimmune diseases . 
Objectives: To determine the circulating serum levels of two Th I (IL-2, IFN-y) and 
two Th2 (IL-6, IL-13) cytokines in patients with systemic lupus erythematosus (SLE), to 
compare serum level of IL-2, IFN- y, IL-6 and IL-13 with the disease activity in SLE 
patients and to assess the relationship between serum level of cytokines (IL-2, IL-6, lL-
13 and IFN-y) and different organ involvement in SLE patients. 
Methodology: We included 90 SLE patients and 30 healthy controls in this 
comparative cross sectional study carried out in Hospital Universiti Sains Malaysia 
(USM) and General Hospital Kota Bharu from October 2003 until September 2005 by 
selecting SLE patients in medical wards and outpatient clinics. Serum levels of cytokines 
were measured by ELISA (IL-2, interferon (IFN) y, IL-6 and IL-13) as well as anti-
dsDNA, ANA, C3 and C4 complement levels were determined. Disease activity was 
recorded according to the Systemic Lupus Erythematosus Disease Activity Index 
Xll 
(SLEDAI) and classified as high activity (SLEDAI > 8) or low activity (SLEDAI :S 8). 
Different organ affected at any time during the course of the disease was recorded. 
Results: The mean age of the patients was 31 .0± 10.8 years. Out of 90 SLE patients, 81 
were females (90%) and 9 males (10%). Majority was Malay (92.2%) and the rest was 
Chinese (7.8%). 52 patients (57.8%) were inactive SLE (SLEDAI score 0-8) and 38 
patients (42.2%) active SLE (SLEDAI score >8). Serum levels of cytokines in SLE 
patients were significantly higher than in healthy control with the exception of IL-2 (IFN-
'Y p<O.OO 1, IL-6 p<O.OO 1, IL-13 p=0.002, IL-2 p= 0.639). There were also significant 
differences between active and inactive SLE patients with the exception of IL-2 (IL-6 p 
<0.001 , IL-1 3 p = 0.009, IFN-y p <0.001and IL-2 p =0.087). There was a positive 
correlation between Th I (IFN- y) and Th2 (IL-6 and IL-1 3) cytokines with the disease 
activity ((IFN-y p=0.002, IL-6 p<O.OO 1, IL-1 3 p=0.006, IL-2 p= 0.151 ). There was 
significant correlation between serum level of IL-1 3 and musculoskeletal invo lvement (p 
=0.0 16) and also IL-6 with haematological involvement (p =0.003). 
Conclusion: The serum levels of Th2 (IL-6 and IL-1 3) and Th I (IFN- y) cytokines 
were significantly elevated and correlated with disease activity in SLE patients. Serum 
cytokine level could provide useful information about di sease activity in SLE patients. 
XIII 
..................... ________________ __ 
ABSTRAK 
Pengenalan: 
SLE adalah satu penyakit autoimun kompleks disebabkan oleh gangguan fungsi sel-sel T-
sitokin yang memainkan peranan penting dalam membentuk kualiti balasan imun 
terhadap antigen sendiri atau asing. Terdapat banyak kajian mengenai peranan sitokin 
dalam penyakit autoimun terutamanya balasan aktif Th 1 yang melibatkan sitokin IFN-y, 
IL-2, IL-12 dan IFN-a. Walaubagaimanapun terdapat perhatian berlainan bahawa sitokin 
jenis kedua (IL-4, IL-5, IL- I 0, IL-6 and IL-13) juga memainkan peranan dalam penyakit 
autoimun ini. 
Objektif: 
Untuk menentukan paras serum 2 Th I sitokin (IL-2, IFN-y) dan 2 Th2 (IL-6, IL-13) 
sitokin dalam penyakit SLE, serta membanding paras serum sitokin IL-2, IFN-y, IL-6 dan 
IL-13 dengan aktiviti penyakit SLE dan akhirnya untuk menentukan hubungan antara 
paras serum sitokin (IL-2, IL-6, IL-13 dan IFN-y) dengan organ-organ yang terlibat 
dengan penyakit SLE. 
Metodologi: 
Kami mengenalpasti 90 pesakit SLE dan 30 individu sihat sebagai control. Kajian rentas 
dilaksanakan di Hospital Universiti Sains Malaysia (HUSM) dan Hospital Kota Bharu 
(HKB) daripada Okt 2003 sehingga September 2005 dimana pesakit dipi lih melalui wad-
wad perubatan dan klinik pesakit luar. Paras sitokin di ukur menggunakan teknik ELISA 
(IL-2, interferon IFN-y , IL-6 dan IL-1 3) dan juga paras anti -dsDNA, ANA, komplemen 
X IV 
C3,C4 turut diukur. Aktiviti penyakit direkodkan berdasarkan Indeks Penyakit SLE 
(SLEDAI: SLE Disease Activity Index) dan diklasifikasikan sebagai akitiviti tinggi 
(SLEDAI > 8) atau aktiviti rendah (SLEDAI~8). Pelbagai penglibatan organ semasa 
penyakit tersebut dihidapi turut direkodkan. 
Keputusan: 
Purata umur pesakit adalah 31.0± 10.8 tahun. Daripada sembilan puluh pesakit SLE, Iapan 
puluh satu adalah wanita {90%) dan sembilan pesakit adalah lelaki (I 0%). Majoriti 
adalah Melayu (92.2%) dan yang lain adalah Cina (7.8%). 52 pesakit (57.8%) adalah 
pesakit SLE inaktif (SLED AI skor 0-8) dan 38 pesakit ( 42.2%) adalah pesakit SLE yang 
aktif (SLEDAI > 8). Paras serum sitokin IFN- y, IL-6 dan IL-I3 adalah lebih tinggi 
dikalangan pesakit SLE berbanding dengan individu yang sihat kecuali IL-2 (.IFN-y 
p<O.OOI, IL-6 p<0.001, IL-13 p=0.002, IL-2 p= 0.639). Terdapat perbezaan signifikan 
antara pesakit SLE aktif dan bukan aktif kecuali IL-2 (IL-6 p <0.00 I, IL-I3 p = 0.009, 
IFN-y p <0.00 I and IL-2 p =0.087) Selain daripada itu, terdapat hubungan antara sitokin 
Th 1, (IFN-y) dan Th2 {IL-6, IL-I3) dengan aktiviti penyakit (IFN-y p=0.002, IL-6 
p<O.OOI, IL-13 p=0.006, IL-2 p= 0.151). Akhirnya, terdapat hubungan signifikan antara 
paras serum IL-13 dengan penglibatan 'muskuloskeletal'(p =0.016) dan juga IL-6 dengan 
system 'hematologi' (p =0.003). 
Kesimpulan: 
Paras serum sitokin Th2 (IL-6 dan IL-13) dan Th I (IFN-y) didapati bertambah dengan 
signifikan serta mempunyai hubungan dengan aktiviti penyakit dikalayan pesakit SLE. 
XV 
Paras serum sitokin boleh menbekalkan maklumat bermanfaat mengenai aktiviti penyakit 
SLE. 
xvi 
CHAPTER ONE 
Introduction 
1.0 Systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized 
clinically by protean manifestations, most commonly including arthralgia, arthritis, rash, 
alopecia, oral ulcers, serositis, leukopenia, central nervous system and renal involvement 
(Lahita, 2004). It is an important prototype of systemic autoimmunity and it causes 
significant disability and premature death in those patients who suffer from it (Lahita, 
2004). 
1.1 Epidemiology 
Primarily, SLE is a disease of young women of childbearing age between 15 to 40 years old 
and female to male ratio of 9: I during this period. Uramoto and colleagues in Minnesota, 
USA, reported that the incidence of SLE is more than tripled over the past four decades. 
(Uramoto, 1999). In Malaysia, it is estimated that more than I 0,000 people have been 
diagnosed with SLE over the past 30 years, with the prevalence of 43 per I 00 000 
population (Wang et al, 1997). However, this number may be only the tip of the iceberg. 
The Malaysian SLE Association believes that there are many more SLE sufferers in 
Malaysia who have not been diagnosed (upusmalaysia.org, 2005). However, the onset of 
disease can range from infancy to old age. SLE affects approximately I in 2000 individuals 
in the general population, although the prevalence varies with race, ethnicity and 
socioeconomic status (Ward, 1995). Estimation of the exact incidence of SLE in United 
State varies; it is reported that it was 124 cases per 100 000 (Hochberg, 1997). But some 
reports indicate that because of improved diagnostic measures, the incidence of SLE is 
increasing. It has been found that mean age at the onset of symptoms was 29 years and at 
the fulfillment of 4 ARA criteria for the diagnosis of SLE. Systemic lupus erythematosus 
(SLE) is the most diverse of the autoimmune diseases because it may affect any organ of 
the body and display a broad spectrum of clinical and immunological manifestations 
(Cervera, 2005). For example, in a study covering a span of greater than 40 years found that 
the pooled incidence of SLE is more than tripled from 1.51/100,000 during 1950 to 1979 to 
5.56 /100,000 during 1980 to 1992 (Uramoto et al, 1999). A recent review of 19 studies 
published from 1995 to 2000, has been reported an even higher incidence rate 7.31100 000 
(Ruiz-Irastorza, 2000). The incidence of SLE is about 3 times higher in African American 
women than in white women (Fessel, 1988), while in the West, it has been shown that 
Blacks are more prone to get SLE compared to Caucasians (Fessel, 1988). In the United 
States morbidity and mortality appear to be greater among Hispanic than among Whites 
(Bonguel, 2002). 
SLE is also common among Asian and Chinese and an increased prevalence of SLE has 
been noted in people of oriental race (Frank, 1980). The ethnic group at the greatest risk is 
African Caribbean Blacks (Molok.hia, 2001) but in another study (Hopkinson, 1994) the 
highest rate is shown in African Caribbean (207 /1 00,000), followed by Asian 
( 48.8/1 00,000) and Whites (20.3/1 OO,OOO).The mean time between the first manifestation 
and the final diagnosis of SLE was 2 years (Cervera, 2005). In the Euro- Lupus cohort, 90 
2 
patients (9%) developed the disease after the age of 50 and (9%) patients with SLE were 
men. 
1.2 Aetiology 
The exact patho-aetiology of systemic lupus erythematosus (SLE) remains elusive. An 
extremely complicated and multifactorial interaction among various genetic and 
environmental factors are probably involved (Mok, 2003). Systemic lupus erythematosus is 
a complex disorder that occurs as a consequence of a number of independent processes and 
factors. Environmental factors, such as viruses, exposure to chemicals, sunlight trigger 
inflammatory or immune activity. Multiple genes contribute to disease susceptibility (Mok, 
2003). The concordance of the disease in identical twins is approximately 25-50% and that 
in dizygotic twins is around 5% (Pisetsky, 1997). The immune activation may begin as an 
appropriate response to an unwanted "invader". But, because of a combination of genetic 
factors, an individual with lupus develops an ongoing immune response that does not shut 
itself off appropriately. Genetic predisposition, sex hormones and environmental factors 
may play an important role in the pathogenesis of SLE (Belmont, 2000). The genetic 
susceptibility can be explained as follows: The concordance of SLE in identical twins, the 
increase in frequency of SLE among first degree relatives and the increased risk of 
developing the disease in siblings of SLE patients reflects a polygenic inheritance of the 
disease. Many different genes contribute to disease susceptibility. In a small proportion of 
patients(< 5%), a single gene may be responsible. For instance, patients with homozygous 
deficiencies of the early components of complement are at risk of developing SLE or a 
lupus-like disease (Walport, 1998). For most of the remaining patients, multiple genes are 
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required. Population studies reveal that the susceptibility to SLE involves human leucocyte 
antigen (HLA) class II gene polymorphisms. An association of HLA DR2 and DR3 with 
SLE is a common finding in patients of different ethnicities, with a relative risk for the 
development of disease of approximately two to five (Pisetsky, 1997). The HLA class II 
genes have also been associated with the presence of certain auto-antibodies such as anti-
Sm (small nuclear ribonuclear protein), anti-Ro, anti-La, anti-nRNP (nuclear ribonuclear 
protein) and anti DNA antibodies(Schur, 1995). SLE is associated with inherited 
deficiencies of C1q, C1r/s and C2 (Atkinson, 1986). A decrease in complement activity 
could promote disease susceptibility by impairing the neutralisation and clearance of self 
and foreign antigens. When the antigen burden overwhelms the clearance capacity of the 
immune system, autoimmunity may ensure (Lau, 2003). 
1.2.1 Sex hormone 
Sex hormones play a part in the pathogenesis of SLE (Manolios and Schrieber, 1997). SLE 
is predominantly a female disease (Cervera, 1993). First onset of SLE before puberty and 
after menopause is uncommon (Formiga, 1999). The female predilection becomes less 
pronounced outside the reproductive age range. In addition, patients with Klinefelter's 
syndrome, characterised by hypergonadotrophic hypogonadism, are prone to the 
development of SLE (French, 1983). These observations suggest a role for endogenous sex 
hormones in disease predisposition. Abnormal oestrogen metabolism has been 
demonstrated in patients with SLE of both sexes, with an increase in 16a hydroxylation of 
oestrone, resulting in significantly raised 16a hydroxyestrone concentrations (Lahita RG, 
1979). The 16a metabolites are more potent and feminising oestrogens. Women with SLE 
also have low plasma androgens, including testosterone, dihydrotestosterone, 
4 
dehydroepiandrosterone (DHEA), and dehydroepiandrosterone sulfate (Jungers, 1982). The 
concentrations of androgens correlate inversely with disease activity (Lahita, 1987). Low 
concentrations of plasma testosterone and raised lutein ising hormone (LH) values (Lahita, 
1987) have been found in some men with SLE. Some studies have found that exogenous 
exposure to estrogen, either through oral contraceptive or oestrogen replacement therapy 
may increase the incidence of SLE (Sanchez-Guerrero et. al, 1997). Taken together, 
oestrogens may aggravate SLE by prolonging the survival of auto-immune cells, increasing 
T helper type 2 (Th2) cytokine productions and stimulating B cells to produce 
autoantibodies. The inhibition of the Th I response and the enhancement of CD40L 
expression on lupus T cells may indirectly promote the Th2 response and lead to further B 
cell hyperactivity (Mok, 2003).The effects of oestrogen is shown in table 1.1 and the role of 
hormones in SLE is summarized in table 1.2. 
5 
Table 1.1 Effects of oestrogen on immune function 
Cell type Effect Dose 
B cells t B cell diffentiation and in vitro Ig production including anti- Physiological 
dsDNA 
(patients with SLE and healthy subjects) 
! In vitro apoptosis of PBMCs and ! TNF-a production (patients Physiological 
with SLE, not in healthy subjects) 
T cells ! Proliferative response to nitrogen and antigens High 
! 1L-2R expression and IL-2 production in activated peripheral High 
blood T cells (healthy subjects) 
t Calcineurin mRNA values in cultured T cells (patients with SLE, Dose dependent 
not in healthy control or patients with other rheumatic diseases) 
t CD40L Expression of peripheral blood T cell (patients with SLE, Physiological 
not in healthy controls) 
Monocytes t IL-l 0 production (patients with SLE and healthy subjects) Physiological 
t eNOS release Physiological 
Others Adhessive molecule expression in endothelial cells High 
CD40L, CD40 ligand eNOS, cytoplasmic nitric oxide synthase. dsDNA, double stranded DNA. /g, immunoglobulin; IL, 
interleukin. IL-2R, interleukin 2 receptor. PMBC, peripheral blood mononuclear cells. SLE, system lupus 
erythematogus. TN F-a, tumour necrosis factor a 
Adapted from a Journal by Mok CC, Lau SC 2003. Pathogenesis of systemic lupus 
erythematosus, Clinical pathology 2003:56, 3. 
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Table 1.2 Role of hormones in human SLE 
Role of hormones in human SLE 
Susceptibility to SLE development 
• Low endogenous oestrogen concentrations are protective 
• Low androgen values in men increase risk 
• Use of exogenous oestrogen increases risk in women 
Hormonal profile and HP A axis in patients with SLE 
• Increase in metabolism of oestrogen to more potent metabolites (both sexes) 
• Low androgen values (both sexes). Androgen values correlate inversely with 
disease activity in women 
• Hyperprolactinaemia occurs in a subset of patients (both sexes). Prolactin 
concentrations correlate with disease activity in some studies. Bromocriptine is 
beneficial in mild SLE 
• Preliminary evidence for a defective HP A axis in untreated female patients with 
SLE 
Hormones, SLE activity and prognosis 
• Disease activity tends to reduce after menopause 
• Flares of SLE may occur during periods of rapid hormonal changes 
• Cyclical fluctuation of disease activity in women during the menstrual cycle 
• Patients with postmenopausal onset SLE have lower disease activity and better 
prognosis 
HPA, hypothalamus- pituitary- adrenal; SLE, systemic lupus erythematosus. 
Adapted from a journal by Mok CC, Lau SC 2003. Pathogenesis of systemic lupus 
erythematosus, Clinical pathology 2003:56,3. 
1.2.2 Environmental factors 
Possible environmental factors including ultra-violet radiation, drugs (e.g., procainamide, 
hydralazin and isonaizide ), infectious agent and severe emotional/physical stress are 
implicated in triggering SLE activation. Several viral infections have been suspected to 
play at least a provoking role (Osmola, 2004). These factors can lead to flare up of lupus 
(Shapiro, 2004; Manolios, 1997). 
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Diagrammatic representation of different factors involved in Systemic lupus erythematosis 
pathogenesis is shown in figure 1.1: 
Genetic 
Suscreptibility 
MHC 
Regulartors of apoptosis 
Cytokines 
Fe Receptors 
Signaling Pathways 
Clearance of apoptotic 
Debris 
Costimulatory 
Interactions 
Immune 
Dysregu lation 
B cells 
T cells 
Dendritic cells 
Triggering 
Factors 
Figure 1.1 Theoretical representation of pathogenesis of SLE (Adapted from a journal by Giovanni F, Elena P, Betty 
D, Pathogenesis of SLE: implications for rational therapy, Disease Mechanism, Autoimmunity and inflammatory 
disease. Drug Discovery Today, Vol , 1, No.3 , 2004) 
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1.3 Immunopathogenesis 
SLE is characterized by alterations in many different parts of the immune system. The basic 
pathological features of SLE are inflammation and blood vessel abnormalities, which 
include band or occlusive vasculopathy, vasculitis and immune complex deposition (Mok, 
2003). Patients may share some central characteristics; a lack of tolerance and the 
production of pathogenic autoantibodies with immune complex formation. 
1.3.1. Disturbances of the immune response 
To better understand the pathogenesis of SLE, the contributions of various cell types have 
been examined. A model of possible T cell-antigen-presenting cell interactions is shown in 
figure 1.2. 
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CD4+ 
TCe/1 
Figure 1.2. Model of possible T cell-antigen presenting cell interactions (Adapted from a journal by Robert 
W. Hoffman. T cells in the pathogenesis of systemic lupus erythematosus Clinical Immunology 2004; 113: 4-
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Figure 1.2 illustrates hypothetical points of the T cell-antigen presenting cell interaction 
which could lead to loss of immunological tolerance in SLE. It appears that there may be 
multiple immunological abnormalities that can lead to breaking of immunological self-
tolerance and several of these may be simultaneously operative. In this model, self-antigen 
(Ag) is taken up by an antigen-presenting cell, processed and presented to T cells. T cell 
receptor signaling events lead to T cell activation and the production of soluble factors, 
such as cytokines, that may in turn provide help to autoantibody-producing B cells, assist in 
the recruitment of other cells to sites of inflammation or in some instances directly mediate 
tissue damage. Structural modification of antigen, abnormalities of antigen processing 
excess co-stimulation via accessory molecules, adjuvant-like signals through Toll-like 
receptors or abnormal activation threshold of T cell receptor could each contribute to 
breaking of immunological tolerance and be important in the pathogenesis of SLE. 
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Potential abnormal signaling points or pathways that could lead to loss ofT cell tolerance 
in SLE are indicated. There is evidence for contributions by B cells, dendritic cells, 
nonlymphoid cells at sites of tissue injury and T cells to the development of SLE 
(Horowitz, 1997) 
1.3.2 Immunotolerance 
Current dogma suggests that triggering factors in a susceptible host result in the loss of self-
tolerance and the development of autoreactivity. A fundamental process in autoimmune 
disease is the breakdown in immunological tolerance either central or peripheral Central 
tolerance involves thymic deletion of self reactive cells and upregulation ofT -cells with 
low affinity of self-MHC. The peripheral T -cell tolerance includes anergy (loss of co-
stimulatory signals) of reactive T -cells, ignorance of antigen by the immune system and 
suppression of autoreactive T -cells. Failure to become tolerant to self antigens, cross-
reactivity and molecular mimicry, development of anti-idiopathic antibodies that cross-
react with self antigens and polyclonal stimulation of naturally occurring autoantibody 
producing cells may underlie the initiation and maintenance of autoantibodies secretion 
(Manolios and Schrieber, I 997). 
1.3.3 Apoptosis 
Apoptosis is viewed as programmed cell death or cellular suicide. The main characteristic 
of apoptotic cells is that they, in contrast to necrotic cells, maintain their membrane 
integrity. The release of intracellular components is thereby prevented. Apoptotic cells are 
usually cleared by macrophages via a noninflammatory pathway (Voll, 1997). Apoptotic 
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and necrotic cells are strong candidates as sources of autoantigens that drive the 
autoantibody response in autoimmune diseases. The fast and efficient uptake of dying cells 
is of main importance to prevent contact of the immune system with intracellular 
autoantigens (Rovere, 2000). Defects in the clearance of dying cells may contribute to the 
etiopathogenesis of systemic lupus erythematosus (SLE). Increased apoptosis or impaired 
clearance of apoptotic cell material has been implicated in the pathogenesis of human SLE. 
Impaired clearance functions for dying cells may explain accumulation of apoptotic cells 
and subsequently of secondary necrotic cells in various tissues of SLE patients. During cell 
death by necrosis or apoptosis, autoantigens are cleaved or otherwise modified. These 
modifications may render cryptic epitopes immune dominant. Dendritic cells may then 
acquire modified autoantigens, like apoptotic nuclei and chromatin and consequently start 
an immune reaction. Nonnally, apoptotic cells are swiftly removed by phagocytosis due to 
surface changes induced by the apoptotic process (Savill, 2002). This prevents the release 
of intracellular constituents, including nucleosomes, which are uniquely fonned during 
apoptosis through cleavage of chromatin by nucleases. However, antibodies against 
nucleosomes are a hallmark of systemic lupus erythetnatosus (SLE) (Dieker, 2002). 
Therefore, disturbances in either apoptosis or the phagocytosis of apoptotic cells have been 
proposed to play a role in the development of autoitnmunity, especially in SLE 
1.3.4. Cellular defect 
SLE is characterised by a myriad of immune system aberrations that involve B cells, T cells 
and cells of the monocytic lineage. This results in polyclonal B cell activation, increased 
numbers of antibody producing cells, hypergammaglobulinaemia, autoantibody production 
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and immune complex formation. It appears that excessive and uncontrolled T cells help in 
the differentiation and activation of autoantibody forming B cells is probably a final 
common pathway (Mok, 2003). The activation of B and T cells requires stimulation by 
specific antigens. Irritating chemicals such as pristine, bacterial DNA and cell wall 
phospholipids and viral anti~ens can induce anti-DNA antibodies in mice (Hahn, 1995). 
Moreover, self antigens, such as DNA-protein and RNA-protein complexes may induce 
autoantibody production (Klinman, 1991 ). Environmental antigens and self antigens are 
taken up by professional antigen presenting cells (APCs) or bind to induced antibodies on 
the surface of B cells. Both professional APCs and B cells process the antigens into 
peptides and present them to T cells through their surface HLA molecules. The activated T 
cells in tum stimulate the B cells to produce pathogenic autoantibodies. In addition to 
contact stimulation, the interaction of B and T cells is facilitated by several cytokines, such 
as IL-l 0. The number of B cells at all stages of activation is increased in the peripheral 
blood of patients with active SLE (Klinman, 1991 ). These B-cell abnormalities can precede 
the development of SLE. Activated lupus B-cells have higher intracytoplasmic calcium 
responses than controls (Liossis, 1996). There is also evidence that B cells in patients with 
SLE are more sensitive to stimulatory effects of cytokines such as IL-6 than non-SLE B 
cells (Linker-Israeli, 1991). Moreover, the phenomenon of epitope spreading has been 
demonstrated in both human and murine SLE (Monneaux, 2002). Thus, it appears that B-
cells in patients with SLE are more prone to polyclonal activation by antigens, cytokines 
and other stimuli. Abnormalities in T cell function are also evident in patients with SLE. 
The total number of peripheral blood T cells is usually reduced, probably because of the 
effects of antilymphocyte antibodies (Bakke, 1983). There is an increase ofT cell function 
towards B cell activation, leading to enhanced antibody production (Linker-Israeli, 1990). 
13 
Figure 1.3 summarises the different pathways in the control of autoimmune reactivity in 
SLE. 
B 
r 'r 
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n I' \ 
AutoAb C-
lmmunocompleJtes 
in ~kidney 
The control of autoimmune reactivity in SLE mediated by CD4+ CD25+ T R and CD8+ Ts 
cells T R and T s may control several events leading to production of the autoantibodies that 
fix the complement and cause tissue damage. APC, antigen presenting cell; Th, CD4+ T 
helper cell ; 8, 8 cell; T R, CD4+ CD25+ regulatory T ce ll ; TS, CD8+ suppressor T cel l; 
Autoantibodies; M<p, macrophage, C, complement. 
Figure 1.3 A schematic model of control of autoimmune reactiv ity in SLE (Adapted from a 
j ournal by Antonio La Cava, Celia J. Fang, Ram. P. Singh, Fanny Ebling, 8evra H. Hahn, 
Manipulation of immune regulation in systemic lupus erythematosus. Auto immunity 
Reviews, 2005 ; 4: 515- 519. 
1.3.5. Role of antibodies 
The presence of pathogenic auto-antibodies is a hallmark of SLE and reinforces the concept 
that 8-cells have a key role in this disease. Auto-antibodies can be seen in healthy 
individuals, although these natural auto-antibodies are usua ll y of a low affinity IgM 
isotype. They do not undergo maturation and do not cause auto immune d iseases or t issue 
damage (Tsokos, 2002). The auto-antibodies production in SLE is thought to be of 
pathogenic relevance, mainly by the formation of immune complexes, with deposition in 
target tissues such as g lomeruli , heart, skin and vessels. T he deposited immune complexes 
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then participate in inflammatory processes involving complement activation, eventually 
causing tissue damage. B cell are important in SLE as they produce antibodies against 
nuclear and cell surface antigens. B cell hyperreactivity is present in SLE and this results in 
the production of a variety of auto-antibodies, including those against nuclear antigens that 
contain chromatin (DNA histone) and uridylate-rich (U) small nuclear ribonucleoproteins 
(U-RNP or U-snRNP that are ribonucleoproteins contained within the spliceosome 
complex) (Maddison, I977). Auto-antibodies against chromatin and ribonucleoprotein are 
serological hallmarks of SLE and their presence is used to help define the syndrome (Tan, 
1982). While virtually I 00% of SLE patients will have antibodies against a nuclear antigen 
(Holyst, 1998; Greidinger, 2003), only 30-50% of patients will have antibodies against one 
of the two nuclear antigens that are considered pathognomonic of SLE, double-stranded 
DNA ( dsDNA) and the Sm antigen of the U-small nuclear ribonucleoprotein complex 
(Greidinger, 2003; Holyst, I998). A higher percentage of SLE patients will have antibodies 
against single-stranded DNA and histones, although the presence of these antibodies is not 
specific for SLE. Anti-nuclear antibodies can be detected months to years preceding the 
development of SLE. However, the development of some auto-antibodies (such as those to 
ribonucleoprotein, Sm and dsDNA) is temporally closely linked to disease onset, 
suggesting that they play a role in the pathogenesis (Arbuckle, 2003). 
1.3.6. Cytokines in SLE 
Cytokine production in patients with SLE differs from both healthy controls and patients 
with other diseases such as rheumatoid arthritis (RA ) (Gillian, 2000). Cytokines have been 
functionally divided into 2 subgroups: Th I, mainly interleukin IL-2, IL-12, interferon 
15 
(IFN)y and tumor necrosis factor (TNF) a and ~, which mainly activate the cellular 
machinery of the immune system; and Th2 (IL-4, IL-5, IL-6, IL-l 0, and IL-13) cytokines, 
which activate the humoral machinery (Funauchi, 1998; Mosmann, 1989). In patients with 
SLE, B-cell hyperactivity has been associated with a high production of Th2 cytokines. 
However, the participation of Th 1 cytokines has been equally demonstrated 
(Theofilopoulos, 2001 ). Both Th 1 and Th2 cytokines can participate in promoting or 
inhibiting auto-immune diseases; thus, a clear-cut distinction between Th 1 and Th2 patterns 
is not without complexity (Amerio, 2002). It is important to note that cytokine production 
is not only changed in patients with SLE when compared with healthy controls but also 
changes with different disease phenotypes. For example, interleukin 6 (IL-6) seems to be 
increased in the cerebrospinal fluid (CSF) of patients with central nervous system (CNS) 
involvement in SLE but not in patients with SLE who lack neurological symptoms (Jara LJ, 
1998). It may be that as in other inflammatory diseases, the balance of cytokines is more 
important in determining disease phenotype or severity rather than in determining disease 
susceptibility. The production of IFN-y by peripheral blood mononuclear cells (PBMC) 
from patients with SLE is significantly correlated with global disease activity score, the 
Systemic Lupus Activity Measure (SLAM) (Spronk, 1993 ). It has been shown that there is 
a correlation between the subclass of antinuclear antibodies and the severity of SLE. All 
auto-antibodies found in subacute cutaneous lupus were of the IgG 1 subclass while IgG2 
and IgG3 auto-antibodies were also found in patients with systemic disease. IFN-y is able 
to induce class switching to production of IgG2 and lgG3. IL-6 is necessary for bone 
marrow targeted plasma cell (CD38+, CD 19+) survival and subsequent 
maturation.(Kawano, 1995) It has been suggested that IL-6 is involved in the autocrine 
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route that maintains B cell hyperactivity (Kawano, 1995). High levels of IL-6 have been 
shown to be implicated in the development of cardiopulmonary disease, which can take the 
form of pericarditis, valvular abnormalities (25%), pleural effusions, lupus pneumonitis, 
pulmonary hypertension and interstitial pneumonitis. Nine patients with lupus nephritis 
were shown to have increased plasma concentrations of IL-6 and siL-6R as compared with 
five normal controls (Horii, 1993). IL-6 is detectable in the urine of patients with lupus 
nephritis and may constitute a useful diagnostic marker (Horii, 1993) 
Skin disease 
IL2, IL4 and ILS mRNA in skin 
biopsies (undetectable in normal controls) 
IL 10 mANA less frequent 
(ubiquitous in controls) 
IL6 and IL 1a increased 
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Renal disease 
Local production of ILS in kidney 
biopsies. High levels in urine. Increased in 
serum 
IFNy, TN Fa, IURa, IL4 and 
IL10 increased in serum 
IL2 and TGF~ reduced in serum 
Neurological disease 
IL 1 and IL6 increased in CSF 
IL2 and TNF undetectable in 
CSF. Serum IL6 no different 
from disease controls 
Figure 1 Summary of abnormal c.ytokine profiles in skitl, kidne)' and tleurt.7/ogfcal syuem.s. 
Figure 1.4 A summary of cytokines profile in skin, kidney and neurological system 
(Adapted from a journal by Gillian S, Dean J. Esther, David A, Isenberg. Cytokines and 
systemic lupus erythematosus. Ann Rheum Dis, 2000; 59:243-251, 2000) 
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Derangement of T cell function has been widely demonstrated in SLE with abnormal 
cytokine profiles correlated to loss of immune tolerance, increased antigenic load and 
defective B cell suppression. Although early reports described defective Th 1 and excessive 
Th2 responses in lupus, recent data suggest that both Th1 and Th2 cytokines can be 
elevated in lupus patients thus indicating that SLE is a complex disease driven by the 
activation of different lymphokine systems at different time-points, possibly explaining the 
heterogeneity of clinical manifestations (Amerio, 2002). 
1.3.6.1 IL-2 
IL-2 is a cytokine secreted primarily by Th 1 that has been activated by stimulation with 
certain mitogen or by interaction of the T cell receptor complex with antigen/MHC 
complexes on the surfaces of antigen presenting cells. It can act as an autocrine factor by 
driving the expansion of the antigen specific cells, or as a paracrine factor by influencing 
the activity of other cells, either within or outside the immune system. 
1.3.6.2 IFN-y 
IFN-y is the principle Th 1 effector cytokine within 2 matn functions. It activates 
macrophages and enhances their microbiocidal activity. Apart from that, IFN-y also 
stimulates the production of lgG antibodies which bind to high-affinity Fe receptors and 
complement proteins, therefore being the principle antibodies involved in the opsonisation 
and phagocytosis of particulate microbes. It also promotes the differentiation of CD8 T 
lymphocytes into active cytotoxic cells (Abbas et al. 1996) 
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1.3.6.3 IL-6 
IL-6 is a cytokine produced by a variety of cells including Th2 during infection, trauma and 
immunological challenge. It promotes inflammatory events through the expansion and 
activation ofT -ceiis, diffentiation of B-cells and the induction of acute-phase reactants by 
hepatocytes. On the other hand, it also has a protective role during disease process and 
counteracts the manifestation of certain inflammatory responses such as septic shock 
(Jones et al, 200 I) 
1.3.6.4 IL-13 
IL-13 is a cytokine produced by Th2 and has an important anti-inflammatory role. Its 
inhibitory effect can lead to a decrease production of IL-l, IL-6, IL-8 and TNF (Chen et al 
2001 ). Apart from that, it also affects B lymphocytes by increasing their proliferation and 
the expression of the CD23 surface antigen (Minty et al, 1993) 
1.3.7 Complement system 
Measurement of C3 and C4 levels may support the diagnosis of SLE. The presence of anti-
dsDNA antibodies and hypocomplementaemia strongly suggests the diagnosis of SLE and 
identifies the patient at increased risk for glomerulonephritis. The complement system 
plays a dualistic role in the pathogenesis of SLE: on the one hand deficient function of 
complement may play a very important role in the deficient clearance of apoptotic cells and 
on the other 'normal' or excessive function of complement plays a major role in the 
pathogenesis of inflammation leading to tissue damage and to the symptoms in SLE 
patients. 
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Congenital deficiencies of C2, C4 and especially C I q have a very strong association with 
SLE-like disease. On the other hand, C3 deficiency has a much milder association with 
SLE. Yet C3 is the first common point in all 3 pathways of complement activation. 
Recently it has been shown that C I q receptors on the surface of macrophages are an 
extremely important mechanism in clearing apoptotic cells (Korb and Ahearn, I997). So it 
could well be that SLE and SLE-like disease is mediated through an influence of Ciq on 
macrophages resulting in an inefficient clearance of apoptotic cells. However, in patients 
with C I q deficiency the manifestations of SLE tend to be restricted to the skin and kidneys 
and anti-dsDNA antibodies tend to be not particularly high. So the primary event causing a 
defective clearance of apoptotic cells in most SLE patients is not yet clear. Autoantibodies 
against Ciq may aggravate the defective clearance of apoptotic cells but they are unlikely 
to be the primary event in SLE. Also massive consumption of complement factors of the 
classical pathway may aggravate the deficiency of clearance of apoptotic cells. The second 
role complement plays in SLE patients is through its reaction with immune complexes. 
Immune complexes stimulate complement activation which in turn leads to inflammation. 
1.4 Diagnostic criteria 
The diagnosis of systemic lupus erythematosus is based on both clinical and laboratory 
criteria. The criteria set by the American College of Rheumatology (ACR) are most widely 
used (Hochberg, I997). A person is suspected to have SLE if she/he fulfills 4 out of the 11 
criteria as shown in table 1.3 
20 
Table 1.3: Revised criteria of the American College of Rheumatology for the 
classification of systemic lupus erythematosus 
1. Malar rash Fixed erythema, flat or raised, over the malar eminences tending to 
spare the nasolabial folds. 
2. Discoid rash Erythematous raised patches with adherent keratotic scaling and 
follicular plugging; atrophic scarring can occur in older lesions 
3. Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient 
history or physician observation. 
4. Oral ulcers 
5. Arthritis 
6. Serositis 
7. Renal disorder 
8. Neurological 
disorder 
Oral or nasopharyngeal ulceration, usually painless, observed by a 
physician. 
Non-erosive arthritis involving two or more peripheral joints, 
characterized by tenderness, swelling, or effusion. 
Pleuritis: convincing history of pleuritic pain or rub heard by a 
physician or evidence of pleural effusion or Pericarditis: 
documented by ECG or rub or evidence of pericardia} effusion. 
Persistent proteinuria greater than 0.5 g/day or greater than 3+ if 
quantification not performed or cellular casts: can be red cell, 
haemoglobin, granular, tubular or mixed. 
Seizures: in the absence of offending drugs or known metabolic 
derangements, e.g.uraemia, ketoacidosis or electrolyte imbalance 
or Psychosis: In the absence of offending drugs or known 
metabolic derangements, e.g. uraemia, ketoacidosis or electrolyte 
imbalance 
9. Haematological Haemolytic anaemia: with reticulocytosis or Leucopenia: less than 
disorder 4000/mm3 or Lymphopenia: less than 1500/mm3 or 
Thrombocytopenia: less than 1500/mm. 
10. Immunological 
disorder 
11. Positive ANA 
Anti-DNA: antibody to native DNA in abnormal titre or Anti-Sm: 
presence of antibody to Sm nuclear antigen or (c) Positive finding 
of antiphospholipid antibodies based on: (i) an abnormal serum 
level of IgG or IgM anticardiolipin antibodies; (ii) a positive test 
for lupus anticoagulant using a standard method; or (iii) a false-
positive test for at least 6 months and confirmed by Treponema 
pallidium immobilisation or fluorescent treponami antibody 
absorption test 
An abnormal titre of antinuclear antibody by immunofluorescence 
or an equivalent assay at any point in time in the absence of drugs 
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1.5 Clinical signs and symptoms 
1.5.1. Constitutional 
The constitutional signs and symptoms of SLE often include fever, malaise, weight loss, 
symmetrical arthralgia, myalgia and headache (Greenberg, 1999). Most serious features of 
SLE are persistent fever and weight loss. 
1.5.2. Musculoskeletal 
Over 90 percent of SLE patients have polyarthralgias or polyarthritis because of the disease 
and it is the most common reason that SLE patients seek medical attention. Small joints of 
the hand and wrist are usually affected therefore soft tissue and tendon thickening causes 
swelling of these joints but the effusion is small unlike rheumatoid arthritis. SLE 
arthropathy is usually not erosive or destructive to bone. (Hay, 1995). 
1.5.3. Mucocutaneous 
More than 90 percent of patients with SLE eventually have cutaneous manifestations of the 
disease, including malar rash, discoid rash and alopecia. Approximately two-thirds of SLE 
patients have photosensitivity, defined as a skin rash due to an unusual reaction to sunlight 
(Provost, 1994 ). SLE can be acute, subacute or a chronic disease. 
Some acute manifestations include bullous lesions and generalized erythema, which may or 
may not be photosensitive in nature (Sontheimer and Gillian, 1992). The most 
characteristic clinical feature of subacute cutaneous lesion is superficial, non indurated and 
non-scarring photosensitivity inducing skin rash. 
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In chronic cutaneous SLE, patients may have a discoid rash with scarring. Oral, nasal and 
other mucus membrane lacerations may occur. Raynaud's phenomena occur in 10-45% of 
SLE patients and is the result of vasospasm and muscular damage, especially apparent with 
the classical white, blue and red color changes in the fingers Alopecia is observed in up to 
45 % of SLE patients at some time in the disease or it can occur with some therapies for 
SLE. Hair loss may be diffuse or patchy associated with discoid lesions. 
1.5.4. Serositis 
Inflammatory serositis of the pleura, peritoneum and pericardium occur in 25 % of SLE 
patients. The patients can develop large pleural effusions, pericardia! effusion or ascites. 
These effusions are typically inflammatory and exudative. 
1.5.5. Haematological 
Anaemia, leucopenia and thrombocytopenia are frequent manifestations of SLE and these 
patients often have normocytic normochromic anemia. Coomb' s test is frequently positive 
and circulating anti-erythropoietin antibodies are reported as a possible mechanism of 
anemia in them (Tzioufas et. al, 1997). 
Leucopenia with white blood cells (WBC's) count less than 4000/mm3 or lymphopenia 
with lymphocytes count less than 1500/mm3 on two or more occasions are part of the 
diagnostic criteria of SLE. However, other causes of decreased WBC's counts such as 
malignancy, infection and drug-induced leukopenia should be excluded before attributing 
the low WBC's count to SLE. 
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Thrombocytopenia with a platelets count less than I OO,OOO/mm3 in the absence of other 
causes is found in up to 25 % of SLE patients. However thrombocytopenia is often a 
marker of severe disease with poor prognosis (Reveille et. al, I990). 
1.5.6. Renal 
The kidney is the most commonly involved organ in patients with SLE and is a major cause 
of mortality and morbidity. Lupus nephritis (LN) represents a major clinical manifestation 
and is present in IS% of patients at the time of diagnosis and in approximately 40% during 
the course of the disease (Cervera, I993). Several studies show evidence of nephritis in 
approximately 50-70 % of renal biopsies from SLE patients (Golbus and McCune, I994). 
The clinical manifestations of lupus nephritis that can be seen in SLE patients are 
asymptomatic haematuria and/or proteinuria, nephritic syndrome or chronic renal failure 
(Kong, I996). The renal involvement is due to deposition of immune complexes containing 
anti-dsDNA antibodies in the kidney (Belmont, 2000). Renal biopsy is the gold standard for 
diagnosis and follow-up of LN. However, serial renal biopsies are not feasible due to their 
invasive nature and potential risks. Urinalysis, measurement of 24-h proteinuria and 
creatinine clearance only identifies lupus patients with overt kidney damage but these 
measurements are inadequate to classify the severity of nephritis and fail to detect early 
'silent' disease (Calvani, 2005). 
Cytokines normally produced within the renal parenchyma are overexpressed in LN by 
both resident and infiltrating cells (Neilson, I997). Studies by Masutani et al (200 I) and 
Mitsuteru et al ( I999) both found predominance of Th I cytokines over Th2 in the 
peripheral blood of patients with Class IV nephritis and SLE patients with proteinuria 
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